Therapeutic Potential of Gnetin C in Prostate Cancer: A Pre-Clinical Study

Nutrients. 2020 Nov 26;12(12):3631. doi: 10.3390/nu12123631.


Natural stilbenes have gained significant attention in the scientific community owing to their potential anticancer effects against prostate cancer. We recently reported that Gnetin C, a resveratrol (Res) dimer, demonstrated more potent inhibition of metastasis-associated protein 1/v-ets avian erythroblastosis virus E26 oncogene homolog 2 (MTA1/ETS2) axis in prostate cancer cell lines than other stilbenes. In this study, we investigated in vivo antitumor effects of Gnetin C in two doses (50 and 25 mg/kg, i.p.) using PC3M-Luc subcutaneous xenografts and compared these to Res and pterostilbene (Pter). We found that while vehicle-treated mice revealed rapid tumor progression, compounds-treated mice showed noticeable delay in tumor growth. Gnetin C in 50 mg/kg dose demonstrated the most potent tumor inhibitory effects. Gnetin C in 25 mg/kg dose exhibited tumor inhibitory effects comparable with Pter in 50 mg/kg dose. Consistent with the effective antitumor effects, Gnetin C-treated tumors showed reduced mitotic activity and angiogenesis and a significant increase in apoptosis compared to all the other groups. The data suggest that Gnetin C is more potent in slowing tumor progression in prostate cancer xenografts than Res or Pter. Taken together, we demonstrated, for the first time, that Gnetin C is a lead compound among stilbenes for effectively blocking prostate cancer progression in vivo.

Keywords: Gnetin C; MTA1; prostate cancer; therapy; xenografts.

MeSH terms

  • Animals
  • Anticarcinogenic Agents / therapeutic use*
  • Benzofurans / therapeutic use*
  • Disease Models, Animal
  • Humans
  • Male
  • Mice
  • Prostatic Neoplasms / drug therapy*
  • Stilbenes / therapeutic use*


  • Anticarcinogenic Agents
  • Benzofurans
  • Stilbenes
  • gnetin C